Microbiology Billing Services That Turn Every Culture Into Collected Revenue

Microbiology billing runs on reflex logic generalist billers miss. Culture-to-sensitivity workflows, target-count-dependent molecular panel codes, and MolDX documentation each carry their own coverage rules; one missed linkage between a positive culture and its susceptibility panel can strip revenue before a claim reaches the payer. TransLabs’ microbiology-certified coders close those gaps: 98% clean claims, 27% faster A/R, measurable recovery inside 90 days.

Microbiology Billing Services
0%
Client Retention Rate
0%
First-Pass Claim Rate
0%
Avg. Revenue Growth
0%
Avg. Denial Reduction

Why Microbiology Labs Lose Revenue Every Single Day

Microbiology billing isn’t simple culture-and-code work. Reflex susceptibility rules, panel target-count thresholds, MolDX assessment requirements, and CLIA-tied testing create an environment where a correct claim gets denied; linked to the wrong parent code, diagnosis, or documentation. The loss isn’t one event; it’s a slow bleed across thousands of claims nobody’s watching.

The Five Revenue Leaks Most Microbiology Labs Don't Know They Have

Culture-to-Susceptibility Reflex Miscapture

Respiratory & GI Panel Target-Count Miscoding

Missing MolDX Documentation for Molecular Panels

Polymicrobial Culture Modifier Errors

CLIA Certificate Omission on High-Complexity Testing

Every Microbiology Test Category, Billed With Reflex and Coverage Precision

From routine bacterial cultures to multiplex molecular panels for hospital and outpatient infectious disease testing, our AAPC and AHIMA certified coders know the reflex rules, the target-count thresholds, and the MolDX documentation requirements for every category of microbiology testing.

Bacterial Culture & Identification

CPT 87040–87158

Blood culture with isolation and identification (87040), urine culture quantitative colony count (87086), urine culture with isolation and presumptive identification (87088), throat/aerobic culture (87070), stool culture for Salmonella/Shigella (87045), wound and respiratory cultures, and definitive organism identification (87076–87077).

Key Billing Consideration

87070 and 87086/87088 are frequently denied together under NCCI column 1/column 2 edits when billed for different specimen sources on the same date; Modifier 59 is required to indicate the cultures came from genuinely separate, medically necessary specimens.

Antimicrobial Susceptibility Testing

CPT 87181–87190

Susceptibility by disk diffusion (87181), microdilution or agar dilution (87186), minimum inhibitory concentration (MIC) studies, and susceptibility testing repeated per isolate when a specimen is polymicrobial.

Key Billing Consideration

Susceptibility codes are reflex-only and must be linked to a positive parent culture code on the claim or in the record; CMS guidance confirms 87186 may be billed once per isolate when a specimen yields multiple significant organisms, but the CLIA certificate number must appear on every claim since this is a high-complexity test category.

Fungal & Mycobacterial Studies

CPT 87101–87118

Fungal culture isolation with presumptive identification from skin, hair, or nail (87101) or other sources (87102), mycobacterial AFB smear and culture, definitive fungal identification, and susceptibility testing for antifungal agents.

Key Billing Consideration

Fungal and mycobacterial cultures often require extended incubation periods that generate a separate date-of-service claim from the original specimen accession; billing systems that don't track pending mycobacterial cultures separately routinely lose this revenue to timely-filing deadlines.

Molecular & Multiplex Infectious Disease Panels

CPT 87481–87801, 87631–87637

Respiratory virus panel by target count — 3–5 targets (87631), 6–12 targets (87632), 12–20 targets (87633) — gastrointestinal pathogen panels by target count (87505–87507), and molecular syndromic panels for infectious disease pathogen identification under MolDX policy.

Key Billing Consideration

Most Medicare MACs' MolDX local coverage determinations consider respiratory and GI panels above five targets not medically necessary outside specific high-risk clinical scenarios; billing 87632 or 87633 without documentation supporting the broader panel is one of the most heavily audited denial categories in molecular microbiology.

Rapid Antigen & Immunoassay Testing

CPT 86318–86710, 87275–87899

Rapid influenza antigen (87804), RSV antigen (87420), COVID-19 antigen (87426), group A strep antigen (87880), H. pylori stool antigen (87338), and C. difficile toxin immunoassay (87324).

Key Billing Consideration

Rapid antigen tests carry their own frequency and medical necessity edits distinct from the molecular versions of the same pathogen; billing an antigen and a molecular NAAT for the same organism on the same date without distinct clinical justification triggers duplicate-service denials.

Parasitology & Ova and Parasite Examination

CPT 87169–87209

Ova and parasite examination, direct smear (87177), concentration technique, permanent stained smear for intestinal parasites, and blood smear for malaria or other blood parasites (87207–87209).

Key Billing Consideration

Ordering patterns for O&P testing frequently request multiple specimens across different collection days; billing all specimens under a single date of service instead of the actual collection dates is a common cause of frequency-related denials.

STI & Genitourinary Infection Panels

CPT 87270–87591, 87661

Chlamydia trachomatis NAAT (87491), Neisseria gonorrhoeae NAAT (87591), combined CT/GC panel testing, trichomonas vaginalis NAAT (87661), and herpes simplex virus PCR (87529–87530).

Key Billing Consideration

Many commercial payers require age- or risk-based medical necessity documentation for combined STI panel testing, and claims billed without a supporting screening or symptomatic diagnosis code are a frequent denial trigger in outpatient and urgent care settings.

Our Laboratory RCM Services

TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.

Proficient Across Multiple LIS & EHRs to Simplify Your
Laboratory Management

ChartLogic
Collaborate md
Greenway health
Haemonetics
jane
cgm Labdaq
Modmed
open emr
Harris Data Integrity Solutions
siemens healthineers
Tebra
Oracle Health
Confience
Power path
Benchmark solutions
Xifin
Psyche Systems
veradigm
Turemed Lis
Telcor
Practice pro
novo path
Nextgen Healthcare
Next tech
meditech
Advanced data systems corporation
Logilab
Labware
Lab vantage
labs os
Epic
Dr Chrono
dendi
Corepoint
clinisys
Care Cloud
apex healthware
clinisys copathplus
Advanced md
softlab
athenaone

Serving Labs Across The United States

TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.

Medicare Part B Compliance for Microbiology Testing

Microbiology billing under Medicare Part B carries reflex-testing rules, MolDX documentation requirements, and panel target-count coverage limits that catch generalist billing companies off guard on a routine basis. The combination of Local Coverage Determinations, MolDX technical assessment requirements, NCCI bundling edits, and CLIA certification rules requires dedicated, proactive management.
Local Coverage Determinations (LCDs)

Each Medicare Administrative Contractor maintains its own LCD specifying which ICD-10 codes support coverage for cultures, susceptibility testing, and molecular pathogen panels. TransLabs maintains live LCD databases for every MAC and validates diagnosis code linkage on every microbiology claim before submission.

MolDX Technical Assessment & Z-Codes

Molecular syndromic panels for infectious disease pathogen identification fall under MolDX policy, which frequently requires a Z-Code identifier and a completed technical assessment on file before a claim is payable. TransLabs tracks which of your molecular tests require MolDX registration and confirms documentation is current before claims go out.

Panel Target-Count Coverage Limits

Most MolDX local coverage determinations consider multiplex respiratory and gastrointestinal pathogen panels above five targets not medically necessary outside defined high-risk clinical scenarios. TransLabs validates target count against payer policy and clinical documentation before a broader panel claim is submitted.

NCCI Bundling Edits

Culture codes from different specimen sources billed on the same date, and susceptibility codes billed without their parent culture, are subject to National Correct Coding Initiative edits. TransLabs runs every microbiology claim through an NCCI edit check before it leaves our system, not after a denial arrives.

CLIA Certification Requirements

Antimicrobial susceptibility testing and many molecular assays are classified as high-complexity under CLIA, and claims are denied when the lab's CLIA certificate number is missing or doesn't match the required certificate type. TransLabs verifies CLIA certificate data on every applicable claim.

PAMA Reporting Requirements

Labs meeting the applicable laboratory definition under PAMA carry mandatory private payer data reporting obligations, and microbiology test volumes are frequently part of that reporting base. TransLabs tracks these obligations and ensures reporting deadlines are met.

OIG Work Plan Monitoring

Multiplex respiratory and gastrointestinal pathogen panel overutilization has drawn sustained OIG and payer audit scrutiny in recent cycles. TransLabs builds compliance protocols specifically around current OIG focus areas to reduce your audit exposure before it becomes a problem.

We Bill Microbiology Testing Exclusively, and the Accuracy Shows

Microbiology billing has its own reflex-testing framework, MolDX documentation requirements, panel target-count coverage rules, and CLIA certification structure. TransLabs was built for lab billing; coders stay in microbiology; not chemistry one week and molecular infectious disease the next.

Microbiology-Exclusive Coding Teams

Your coders specialize in microbiology reflex logic, culture-to-susceptibility linkage, panel target counts, MolDX; not every lab discipline at once

98% First-Pass Clean Claims Rate

98%+ clean claims rate across all lab clients with fewer denials, faster payments, stronger cash flow.

Reflex-Linkage Engine

Automated logic ties every susceptibility charge to its parent culture before claims go out; closing LIS-to-billing gaps most labs never see.

Molecular Panel & MolDX Expertise

We get Z-Codes, technical assessment docs, and target-count coverage right from day one; MAC-specific ICD-10 combinations included.

No Long-Term Contracts

Month-to-month, results-based partnership with measurable improvement in 90 days, no exit fees, just 30 days’ notice.

Transparent Reporting

Monthly dashboards with full visibility of clean claims rate, denial trends, A/R aging, and root cause analysis, no surprises.

Get Your Microbiology Lab's Custom Revenue Recovery Plan

Schedule a call with our microbiology billing specialist. We’ll review your culture-to-susceptibility linkage, molecular panel coverage, MolDX documentation, and A/R days.

What Our Clients Say?

Linda Hutchinson
Linda Hutchinson
Laboratory Director
Our NGS panel denials dropped from 32% to under 6% within three months. TransLabs' expertise with molecular tier codes, prior authorization management, and LCD compliance has been invaluable. They understand the nuances of genetic testing billing that our previous vendor completely missed.
Peter Wozniak
Peter Wozniak
Pathologist & Laboratory Owner
We've worked with three other billing companies over the years. TransLabs is the only one that truly understands complex surgical pathology coding, immunohistochemistry billing, and the nuances of TC/PC modifiers. Clean claims rate improved to 99%, and our dermatopathology reimbursement increased 27%.
James Patton
James Patton
Cytogenetics Laboratory Manager
Before TransLabs, our FISH and karyotype claims were a constant struggle with denials and underpayments. Their coders actually understand probe configurations, complexity levels, and when to use 88271 versus 88275. Our cytogenetics revenue increased 34% in the first year.

Book Consultation Today!

Stop Leaving Microbiology Reimbursements on the Table

Join 350+ clinical microbiology labs, hospital laboratories, and molecular diagnostics centers that trust TransLabs, the laboratory billing company built for growth. Start with our complimentary claims audit. Our microbiology billing specialists will review your CPT/HCPCS coding, reflex-linkage accuracy, and denial trends to show you exactly what’s recoverable.

Dedicated microbiology billing specialist assigned to your lab

Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers

Uncover your top 3 revenue leaks in reflex linkage, panel target counts, and MolDX documentation

Custom strategy tailored to your analyzer platform and LIS/billing software

Live in 24 hours with no contracts and no upfront fees

Pay only a percentage of what we collect for you

Frequently Asked Questions

Why does susceptibility testing get denied even when the culture was positive?

Susceptibility codes (87181–87190) are reflex-only and must be linked to a positive parent culture code on the claim or in the record. When a lab’s LIS doesn’t carry that linkage through to the billing system, payers flag the susceptibility charge as lacking medical necessity, even though the test was clinically appropriate.
These respiratory virus panel codes are billed by the number of targets tested, not by test name: 87631 covers 3–5 targets, 87632 covers 6–12 targets, and 87633 covers 12–20 targets. Most MolDX local coverage determinations consider panels above five targets not medically necessary outside specific high-risk clinical scenarios.
MolDX is a Medicare program that governs coverage and documentation for molecular diagnostic tests, including infectious disease pathogen panels. Many molecular microbiology tests require a Z-Code identifier and a completed technical assessment on file before a claim is payable, and claims are denied automatically when that documentation is missing.
Yes. CMS guidance confirms that susceptibility codes may be billed once per isolate when a specimen yields multiple significant organisms, since urinary tract and wound infections are frequently polymicrobial. Modifier 59 is required to distinguish each isolate’s separate susceptibility panel on the claim.
Cultures from different specimen sources billed on the same date; for example, a throat culture and a urine culture are subject to column 1/column 2 NCCI edits that deny one code unless Modifier 59 documents that the cultures came from genuinely separate, medically necessary specimens.
Antimicrobial susceptibility testing by microdilution or agar dilution and many molecular assays are classified as high-complexity under CLIA, requiring a Certificate of Compliance or Accreditation. The CLIA certificate number must appear on the claim, and claims are denied when it’s missing or doesn’t match the required certificate type.
Yes, including chlamydia and gonorrhea NAAT testing, combined CT/GC panels, trichomonas PCR, and herpes simplex virus PCR. Many commercial payers require age- or risk-based medical necessity documentation for combined panel testing, which we validate before claims go out.
Most microbiology labs see measurable improvement within 60–90 days: reflex-linkage corrections and NCCI/MolDX edit checks are live within the first 30 days, denial rate improvement follows by day 60, and by day 90 clients typically see a 98% clean claims rate with documented revenue recovery from previously missed susceptibility and panel charges.

Your Trusted Lab Billing Partner

Book Your Free Consultation

Book Consultation Today!

Book Consultation Today!